Perceptive Advisors’s Kyntra Bio KYNB Stock Holding History

Perceptive Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,000	Closed	-$6.94M	–	157
2021 Q1	$6.94M	Buy	+8,000	New	+$8.52M	0.09%	104

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors's KYNB Position: Q2 2019 in Review

Perceptive Advisors sold out of Kyntra Bio (KYNB) in Q2 2019, closing a stake of 372 shares — an estimated $506K sold.

Perceptive Advisors first reported a position in KYNB in Q3 2017 and held it in 2 quarters. The position peaked at $506K in Q1 2019. 190 funds tracked by Wall St. Rank hold KYNB as of Q2 2019.

Perceptive Advisors reported no remaining Kyntra Bio position as of Q2 2019 after selling out during the quarter.
Perceptive Advisors sold 372 Kyntra Bio shares in Q2 2019, an estimated $506K.
Perceptive Advisors first reported a position in Kyntra Bio in Q3 2017 and held it in 2 quarters.
Perceptive Advisors's Kyntra Bio position peaked at $506K in Q1 2019.
190 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2019.

Based on Perceptive Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.